To evaluate the efficacy of once-weekly DPP-4 inhibitor:Omarigliptin for liver function of type 2 diabetic patients with NAFLD/NASH

Not Applicable

Completed

• Conditions: Type 2 diabetes

• Registration Number: JPRN-UMIN000045957
• Lead Sponsor: Department of Diabetes and Metabolism,Tohto Clinic

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-11-06
• Last Update Posted: 17 October 2023
• Study Completion: 2025-03-31

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

Not provided

Exclusion Criteria

1)Pregnant or being pregnant within the study 2)Contraindication with Dipeptidyl peptidase 4 inhibitor

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting blood glucose,HbA1c and liver function are set to be measured at baseline and once at 3 months for 36 months. Abdominal ultrasonography is set to be examined at baseline and once at 6 months for 36 months.

Secondary Outcome Measures

Name	Time	Method
Body mass index(BMI),body pressure,immunoreactive insulin(IRI),homeostasis model assessment for insulin resistance(HOMA-IR),high-sensitivity C-reactive protein(hsCRP) and lipid function are set to be measured at baseline and once at 3 months for 36 months.